Abstract:Background Urolithiasis is a prevalent condition encountered in urology. Over the past decade, its global incidence has been on an upward trajectory; paired with a high recurrence rate, this presents considerable health and economic burdens. Although inflammatory factors are pivotal in the onset and progression of urolithiasis, their causal linkages remain elusive. Method Mendelian randomization (MR) is predicated upon genome-wide association studies (GWASs). It integrates bioinformatics analyses to reveal causal relationships between exposures and outcomes, rendering it an effective method with minimized bias. Drawing from a publicly accessible GWAS meta-analysis comprising 8,293 samples, we identified 41 genetic variations associated with inflammatory cytokines as instrumental variables. Outcome data on upper urinary tract stones, which included renal and ureteral stones (9,713 cases and 366,693 controls), and lower urinary tract stones, including bladder and urethral stones (1,398 cases and 366,693 controls), were derived from the FinnGen Consortium R9 dataset. By leveraging the bidirectional MR methodology, we aimed to decipher the causal interplay between inflammatory markers and urolithiasis. Results Our study comprehensively elucidated the association between genetic inflammatory markers and urolithiasis via bidirectional Mendelian randomization. Post-MR analysis of the 41 genetic inflammation markers revealed that elevated levels of circulating interleukin-2 (IL-2) (OR = 0.921, 95% CI = 0.848–0.999) suggest a reduced risk for renal stone disease, while heightened stem cell growth factor beta (SCGF-β) (OR = 1.150, 95% CI = 1.009–1.310) and diminished macrophage inflammatory protein 1 beta (MIP-1β) (OR = 0.863, 95% CI = 0.779–0.956) levels suggest an augmented risk for lower urinary tract stones. Furthermore, renal stone disease appeared to elevate IL-2 ( β = 0.145, 95% CI = 0.013–0.276) and cutaneous T cell-attracting chemokine (CTACK) ( β = 0.145, 95% CI = 0.013–0.276) levels in the bloodstream, whereas lower urinary tract stones were linked to a surge in interleukin-5 (IL-5) ( β = 0.142, 95% CI = 0.057–0.226), interleukin-7 (IL-7) ( β = 0.108, 95% CI = 0.024–0.192), interleukin-8 (IL-8) ( β = 0.127, 95% CI = 0.044–0.210), growth regulated oncogene alpha (GRO-α) ( β = 0.086, 95% CI = 0.004–0.169), monokine induced by interferon-gamma (MIG) ( β = 0.099, 95% CI = 0.008–0.191) and macrophage inflammatory protein 1 alpha (MIP-1α) ( β = 0.126, 95% CI = 0.044–0.208) levels. Conclusion These discoveries intimate the instrumental role of IL-2 in the onset and progression of upper urinary tract stones. SCGF-β and MIP-1β influence the development of lower urinary tract stones. Urolithiasis also impacts the expression of cytokines such as IL-2, CTACK, IL-5, IL-7, IL-8, GRO-α, MIG, and MIP-1α. There is a pressing need for further investigation to ascertain whether these biomarkers can be harnessed to prevent or treat urolithiasis.

Serum urate is associated with an increased risk of inflammatory bowel disease: A bidirectional Mendelian randomization study

Assessment of the causal relationship between inflammatory bowel diseases and chronic kidney diseases: A two-sample bidirectional mendelian randomization study among European population

Genetically predicted serum uric acid levels and the risk of coronary artery disease in patients with diabetes: A Mendelian randomization study

Associations of Serum Uric Acid Levels with Liver Disease-Related Morbidity and Mortality: A Prospective Cohort Study of the UK Biobank.

Interleukin-17 and Inflammatory Bowel Disease: a 2-Sample Mendelian Randomization Study

Serum uric acid levels and multiple health outcomes: umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studies

Causal Linkage Between Inflammatory Bowel Disease and Primary Sclerosing Cholangitis: A Two-Sample Mendelian Randomization Analysis

The Role of Inflammatory Biomarkers in Mediating the Effect of Inflammatory Bowel Disease on nonmalignant Digestive System Diseases: A Multivariable Mendelian Randomized Study

Inflammatory bowel disease increases the levels of albuminuria and the risk of urolithiasis: a two-sample Mendelian randomization study

Association between serum uric acid and colorectal cancer risk in European population: a two-sample Mendelian randomization study

Causal relationship between serum uric acid and cardiovascular disease: A Mendelian randomization study

Causal association between inflammatory bowel disease and IgA nephropathy: A bidirectional two-sample Mendelian randomization study

Bidirectional Causal Associations Between Inflammatory Bowel Disease and Ankylosing Spondylitis: A Two-Sample Mendelian Randomization Analysis.

Inflammatory factors and the risk of urolithiasis: a bidirectional Mendelian randomization study

Evaluating the Causal Association Between Inflammatory Bowel Disease and Risk of Atherosclerotic Cardiovascular Disease: Univariable and Multivariable Mendelian Randomization Study.

The causal effects of inflammatory bowel disease on primary biliary cholangitis: A bidirectional two‐sample Mendelian randomization study

Does inflammatory bowel disease promote kidney diseases: a mendelian randomization study with populations of European ancestry

The causal relationship of serum uric acid on colorectal cancer: A Mendelian randomization study

Associaion of Gout with Crohn’s disease, and Inflammatory Bowel Disease with IgA Nephropathy: A Mendelian Randomization

Causal association of blood cell traits with inflammatory bowel diseases: a Mendelian randomization study

Elevated Serum Urate is a Potential Factor in Reduction of Total Bilirubin: a Mendelian Randomization Study.